A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

NCT06969612 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: Tislelizumab
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Albumin Paclitaxel
DRUG: Golidocitinib

Sponsor

Peking University Cancer Hospital & Institute